BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in a form of dwarfism in children. The FDA granted infigratinib, which was ...
Phase 3 findings show infigratinib significantly improved annualized height velocity vs placebo in children living with achondroplasia. Topline data were announced from a phase 3 trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results